Yunlin Fu

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 10

Top Topics

High Resolution Mass Spectrometry

Placebo Controlled

Ultra High Performance Liquid Chromatography

Top Venues

Clinical and translational science

Analytical chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Ewa Gatlik, Beata Mehes, Emilie Voltz, Ulrike Sommer, Elaine Tritto, Giulia Lestini, Xiaoxi Liu, Parasar Pal, Maria Velinova, William S Denney, Yunlin Fu, Anthony Opipari, Dennis Dean, Guido Junge
First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor. Clinical and translational science 17 (5) (2024)
Yunlin Fu, Wenkui Li, Franck Picard
Assessment of matrix effect in quantitative LC-MS bioanalysis. Bioanalysis 16 (12) (2024)
Yunlin Fu, Wenkui Li, Franck Picard
Assessment of matrix effect in quantitative LC-MS bioanalysis. Bioanalysis (2024)
Yunlin Fu, Wenkui Li, Franck Picard
Assessment of matrix effect in quantitative LC-MS bioanalysis. Bioanalysis 16 (12) (2024)
Ewa Gatlik, Beata Mehes, Emilie Voltz, Ulrike Sommer, Elaine Tritto, Giulia Lestini, Xiaoxi Liu, Parasar Pal, Maria Velinova, William S Denney, Yunlin Fu, Anthony Opipari, Dennis Dean, Guido Junge
First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor. Clinical and translational science 17 (5) (2024)
Yunlin Fu, Wenkui Li, Franck Picard
Assessment of matrix effect in quantitative LC-MS bioanalysis. Bioanalysis 16 (12) (2024)
Ewa Gatlik, Beata Mehes, Emilie Voltz, Ulrike Sommer, Elaine Tritto, Giulia Lestini, Xiaoxi Liu, Parasar Pal, Maria Velinova, William S Denney, Yunlin Fu, Anthony Opipari, Dennis Dean, Guido Junge
First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor. Clinical and translational science 17 (5) (2024)
Yunlin Fu, James Farnham, Wenkui Li, Brendan Powers, David Humphries, Franck Picard
LC-MS/MS Bioanalysis of Radioligand Therapeutic Drug Candidate for Preclinical Toxicokinetic Assessment. Analytical chemistry (2023)
Yunlin Fu, Wenkui Li, Franck Picard
Non-regulated LC-MS/MS bioanalysis in support of early drug development - a Novartis perspective. Bioanalysis (2023)
Yunlin Fu, Shashank Gorityala, Wenkui Li, David Humphries, Aaron Ledvina, Stephanie Cape, Franck Picard
Sensitive LC-MS/MS quantification of unconjugated maytansinoid DM4 and its metabolite S-methyl-DM4 in human plasma. Bioanalysis 14 (6) (2022)